FEATURED
EyePoint’s DURAVYU delivers mixed endpoint results in first phase 3 wet AMD trial

Primary endpoint not achieved in full dataset while ad-hoc analysis excluding asymmetric cohort demonstrated non-inferiority to on-label aflibercept.

Earn FREE CE 24/7 with Courses by Eyes On Eyecare

Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.

TRENDING
Research